Vyne Therapeutics Stock Alpha and Beta Analysis

VYNE Stock  USD 2.96  0.13  4.59%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Vyne Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Vyne Therapeutics over a specified time horizon. Remember, high Vyne Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Vyne Therapeutics' market risk premium analysis include:
Beta
1.64
Alpha
0.1
Risk
4.25
Sharpe Ratio
0.11
Expected Return
0.48
Please note that although Vyne Therapeutics alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., NYSE Composite index.) So in this particular case, Vyne Therapeutics did 0.10  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Vyne Therapeutics stock's relative risk over its benchmark. Vyne Therapeutics has a beta of 1.64  . As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Vyne Therapeutics will likely underperform. The current year's Price Book Value Ratio is expected to grow to 0.28. The current year's Enterprise Value Multiple is expected to grow to 0.23.
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Vyne Therapeutics Backtesting, Vyne Therapeutics Valuation, Vyne Therapeutics Correlation, Vyne Therapeutics Hype Analysis, Vyne Therapeutics Volatility, Vyne Therapeutics History and analyze Vyne Therapeutics Performance.
For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.

Vyne Therapeutics Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Vyne Therapeutics market risk premium is the additional return an investor will receive from holding Vyne Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Vyne Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Vyne Therapeutics' performance over market.
α0.10   β1.64

Vyne Therapeutics expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Vyne Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Vyne Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Vyne Therapeutics Market Price Analysis

Market price analysis indicators help investors to evaluate how Vyne Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Vyne Therapeutics shares will generate the highest return on investment. By understating and applying Vyne Therapeutics stock market price indicators, traders can identify Vyne Therapeutics position entry and exit signals to maximize returns.

Vyne Therapeutics Return and Market Media

The median price of Vyne Therapeutics for the period between Fri, Dec 29, 2023 and Thu, Mar 28, 2024 is 2.16 with a coefficient of variation of 11.35. The daily time series for the period is distributed with a sample standard deviation of 0.25, arithmetic mean of 2.17, and mean deviation of 0.19. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
01/03/2024
2
Vyne reports positive data from Phase 1b study for vitiligo drug
01/10/2024
3
Acquisition by Iain Stuart of 62500 shares of Vyne Therapeutics subject to Rule 16b-3
01/31/2024
4
Is Vyne Therapeutics Inc a Stock to Watch After Gaining 16.67 percent This Week - InvestorsObserver
02/05/2024
5
VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium
02/27/2024
6
Vyne Therapeutics files for 250M mixed shelf
03/01/2024
7
Heres Why VYNE Therapeutics Inc. Is a Great Buy the Bottom Stock Now
03/13/2024
8
Is Vyne Therapeutics Inc Stock About to Get Hot Monday - InvestorsObserver
03/25/2024

About Vyne Therapeutics Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Vyne or other stocks. Alpha measures the amount that position in Vyne Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2023 2024 (projected)
Dividend Yield0.0064410.006119
Price To Sales Ratio56.4553.63

Vyne Therapeutics Upcoming Company Events

As portrayed in its financial statements, the presentation of Vyne Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vyne Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Vyne Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Vyne Therapeutics. Please utilize our Beneish M Score to check the likelihood of Vyne Therapeutics' management manipulating its earnings.
14th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Vyne Therapeutics

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Vyne Therapeutics is a strong investment it is important to analyze Vyne Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vyne Therapeutics' future performance. For an informed investment choice regarding Vyne Stock, refer to the following important reports:

Complementary Tools for Vyne Stock analysis

When running Vyne Therapeutics' price analysis, check to measure Vyne Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vyne Therapeutics is operating at the current time. Most of Vyne Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vyne Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vyne Therapeutics' price. Additionally, you may evaluate how the addition of Vyne Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Vyne Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Vyne Therapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Vyne Therapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...